Stručni rad
Prognostic Value of Lactate Dehydrogenase in Patients with Melanoma Treated with Pembrolizumab
Aleksandar Popović
orcid.org/0000-0001-7114-0068
; Clinic of Oncology, University Clinical Center Niš, Serbia
Ivan Petković
orcid.org/0000-0002-9110-4117
; Clinic of Oncology, University Clinical Center Niš, Serbia
Aleksandra Dimitrijevic
; Clinic of Oncology, University Clinical Center Niš, Serbia
Andrija Jović
; Clinic of Dermatovenerology, University Clinical Center Niš, Niš, Serbia
Sažetak
Introduction: Elevated LDH levels have been extensively reported as
a biomarker of poorer outcome in patients with melanoma during the
chemotherapeutic era. The role of LDH level as a prognostic factor for
treatment outcomes in patients with metastatic melanoma treated
with immunooncological therapy has also been reported but requires
further analysis.
Objectives: In this study, we aimed to evaluate the prognostic value
of lactate dehydrogenase (LDH) among patients with metastatic and
unresectable melanoma treated with pembrolizumab in terms of pro-
gression-free survival (PFS).
Methods: The study included 59 patients with unresectable and met-
astatic melanoma treated with pembrolizumab. A comparison was
performed between patients with normal and elevated levels of LDH
in terms of PFS, with subgroup analysis.
Results: There was a significant reduction in PFS among patients with
elevated levels of LDH compared with patients with normal levels of
LDH (NR vs. 5 months; P=0.02). Patients with elevated LDH levels were
older (P=0.01), with liver metastasis (P=0.004), and with less frequent
CNS deposits (P=0.028).
Conclusion: Although novel agents improved outcomes in patients
with melanoma, high levels of LDH persist as an independent prog-
nostic biomarker of poor prognosis.
Ključne riječi
melanoma; pembrolizumab; lactate dehydrogenase
Hrčak ID:
311639
URI
Datum izdavanja:
15.6.2023.
Posjeta: 157 *